Table 3.
Pooled prevalence (PP) of long-term consequences in patients with different severity of COVID-19.
| Consequences | Severity of COVID-19 Disease | |||
|---|---|---|---|---|
| Asymptomatic Infection | Symptomatic Infection | |||
| Total | Mild Cases | Moderate/Severe Cases | ||
| At least one symptom | 17.13 (7.55–26.71) * | 53.02 (44.54–61.49) * | 48.19 (32.78–63.60) * | 66.54 (34.86–98.23) * |
| Fatigue | 9.33 (3.07–15.60) * | 22.07 (11.18–32.95) * | 20.48 (1.42–39.54) * | 40.05 (4.39–75.71) * |
| Headache | 4.49 (0.19–8.80) * | 8.06 (−1.78–17.90) | 8.65 (−5.44–22.73) | 12.20 (−6.36–30.76) |
| Loss of smell | 14.14 (−1.32–29.61) | - | - | - |
| Cough | 6.82 (−0.63–14.27) | 4.02 (0.88–7.15) * | 2.15 (0.67–3.62) * | 7.75 (−2.28–17.78) |
| Hair loss | 1.82 (−1.71–5.35) | 6.38 (1.01–11.76) * | 6.49 (0.79–12.19) * | 4.13 (1.19–7.06) * |
| Loss of taste | 15.09 (5.46–24.73) * | - | - | - |
| Chest pain | - | 3.73 (−2.15 -9.61) | 2.36 (−1.38–6.10) | 7.85 (−5.60–21.30) |
| Cutaneous lesions | 0.81 (−0.01–1.63) | 3.53 (2.40–4.67) * | 3.60 (2.09–5.11) * | 2.80 (0.36–5.25) * |
| Neurological symptoms | 2.51 (0.97–4.04) * | 11.97 (8.35–15.59) * | - | - |
| Dyspnoea | 5.38 (0.70–10.07) * | 13.78 (2.97–24.60) * | 9.84 (0.49–19.20) * | 23.97 (−5.66–53.59) |
| Muscle or joint pains | 3.11 (−0.32–6.35) | 21.00 (−1.63–43.62) | - | - |
| Loss of taste/smell | 2.39 (−3.54–8.31) | 10.61 (8.47–12.75) * | - | - |
| Gastrointestinal symptoms | 1.75 (0.47–3.04) * | 3.18 (−0.27–6.63) | - | - |
| Ocular symptoms | 4.51 (−1.61–10.70) | 3.87 (−3.36–11.10) | 3.12 (−2.57–8.81) | 12.07 (3.69–20.45) * |
| Psychiatric disorders | 2.76 (1.15–4.36) * | 6.65 (3.47–9.84) * | - | - |
| Palpitations and cardiac disorders | 0.28 (−0.21–0.76) | 5.39 (−2.10–12.87) | - | - |
* p-value < 0.05.